SavedAdd your journal

Journals / Marmara Medical Journal / 2008 / Cilt: 21 - Sayı: 3

-

TAM KALINLIKTA NASAL ALAR DEFEKTİN KOMPOZİT KULAK GREFTİ ve HİPERBARİK OKSİJEN TEDAVİSİ İLE ONARIMI

Yakup ÇİL
Mehmet SEZGİN
Pages
296–297
Publication Date
2015-06-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Nasal alar bölge defektlerinin estetik ve fonksiyonel açıdan onarımının yapılması cerrah için oldukça zordur. Literatürde değişik teknikler tarif edilmiş olsada, ideal onarım tekniği mevcut değildir. Biz kompozit kulak grefti ile hiperbarik oksijen tedavisini kombine olarak 21 yaşındaki erkek hastadaki nasal alar defekti için kullandık. Kompozit kulak grefti hiperbarik oksijen tedavisi ile kombine edilerek tam kalınlıktak nasal alar defektlerin onarımında kullanıldığında iyi fonksiyonel ve estetik sonuç sağlanabilir.

🔖

Cite This Article

ÇİL, Y., SEZGİN, M. (2015). -. Marmara Medical Journal, Cilt: 21 - Sayı: 3, 296–297. https://ajindex.com/articles/688474

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Svedman P. Advancement flaps for alar reconstruction. Ann Plast Surg 1990;25(6):502-7
  2. Burget GC, Menick FJ. The subunit principle in nasal reconstruction. Plast Reconstr Surg 1985;76(2):239-47
  3. Keck T, Lindemann J, Kuhnemann S, et al. Healing of composite chondrocutaneous auricular grafts covered by skin flaps in nasal reconstructive surgery. Laryngoscope 2003;113(2):248-53
  4. Lewis D, Goldztein H, Deschler D. Use of hyperbaric oxygen to enhance auricular composite graft survival in the rabbit model. Arch Facial Plast Surg 2006;8(5):310- 13.: 165-176. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in reumatoid arthritis, J Immunol; 152 (8): 4149-4156. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13; 37-50. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the ınhibition of tumor growth and metastasis. Oncogene 2000; 19: 6122- - Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the tie2 receptor, by secretion-trap expression cloning. Cell 1996; 87 (7): 1161-1169. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277 (5322): 55-60. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol 2007; 26: 453-463. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position-460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 2008; 1: 17-22. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230–1237. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev 2007; 31: 102-109. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789–799. Hartsough MT, Steeg PS. Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr 2000; 32 (3)